Publications by authors named "Tim Somervaille"

Claim this Profile
B
Bleeding Complications in JAK2-Variant Essential Thrombocythemia: A Revisit in 2025.
Gerard Gurumurthy, Samantha Gurumurthy, Tim C P Somervaille, Anna Falanga, Jecko Thachil

EJHaem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stromal lipid species dictate melanoma metastasis and tropism.
Shilpa Gurung, Timothy Budden, Karthik Mallela, Benjamin Jenkins, Alex von Kriegsheim, Tim C P Somervaille

Cancer Cell· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-omic analysis of chronic myelomonocytic leukemia monocytes reveals metabolic and immune dysregulation leading to altered macrophage polarization.
Hasse M Addinsell, Rachel Cant, Nathan J Hull, Yu-Hung Wang, Tim C P Somervaille

Leukemia· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An integrative multiparametric approach stratifies putative distinct phenotypes of blast phase chronic myelomonocytic leukemia.
Kristian Gurashi, Yu-Hung Wang, Fabio M R Amaral, Katherine Spence, Rachel Cant, Tim C P Somervaille

Cell Rep Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response.
Naveen Pemmaraju, Tim C P Somervaille, Francesca Palandri, Claire Harrison, Rami S Komrokji

Blood Neoplasia· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conserved role of FOXC1 in TNBC is parallel to FOXA1 in ER+ breast cancer.
Revathy Ramachandran, Shakhzada Ibragimova, Laura M Woods, Tamader AlHouqani, Roshna Lawrence Gomez, Tim C P Somervaille

iScience· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
Vikas Gupta, Stephen Oh, Timothy Devos, Viviane Dubruille, John Catalano, Tim C P Somervaille

Leuk Lymphoma· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.
Olga Salamero, Antonieta Molero, José Antonio Pérez-Simón, Montserrat Arnan, Rosa Coll, Tim C P Somervaille

Lancet Haematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
Donal P McLornan, Anna L Godfrey, Anna Green, Rebecca Frewin, Siamak Arami, Tim C P Somervaille

Br J Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.
Alex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, James Forryan, Fotios Panitsas

Blood· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The management of myelofibrosis: A British Society for Haematology Guideline.
Donal P McLornan, Bethan Psaila, Joanne Ewing, Andrew Innes, Siamak Arami, Tim C P Somervaille

Br J Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Luciano Nicosia, Gary J Spencer, Nigel Brooks, Fabio M R Amaral, Naseer J Basma, Tim C P Somervaille

Cancer Cell· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Francesca Palandri, Timothy Devos, Tim C P Somervaille

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A TIAM1-TRIM28 complex mediates epigenetic silencing of protocadherins to promote migration of lung cancer cells.
Lucy Ginn, Joe Maltas, Martin J Baker, Anshuman Chaturvedi, Leah Wilson, Tim C P Somervaille

Proc Natl Acad Sci U S A· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differentiation block in acute myeloid leukemia regulated by intronic sequences of .
Francesco Camera, Isabel Romero-Camarero, Bradley H Revell, Fabio M R Amaral, Oliver J Sinclair, Tim C P Somervaille

iScience· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients.
Stella Pearson, Rognvald Blance, Fei Yan, Ya-Ching Hsieh, Bethany Geary, Tim C P Somervaille

PLoS One· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia.
Yu-Hung Wang, Chi-Yuan Yao, Chien-Chin Lin, Kristian Gurashi, Fabio M R Amaral, Tim C P Somervaille

Br J Haematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block.
Alba Maiques-Diaz, Luciano Nicosia, Naseer J Basma, Isabel Romero-Camarero, Francesco Camera, Tim C P Somervaille

Oncogene· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
Claire N Harrison, Jacqueline S Garcia, Tim C P Somervaille, James M Foran, Srdan Verstovsek

J Clin Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
Adam J Mead, Nauman M Butt, Waseem Nagi, Alastair Whiteway, Suriya Kirkpatrick, Tim C P Somervaille

Ther Adv Hematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML.
Luciano Nicosia, Francesca Ludovica Boffo, Elena Ceccacci, Fabio Conforti, Isabella Pallavicini, Tim C P Somervaille

Oncogene· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic myeloid leukemia presenting as compartment syndrome with acute loss of upper limb function.
Natasha D'Souza, Tim C P Somervaille, David J Mowatt

Am J Emerg Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancer recruitment of a RUNX1, HDAC1 and TLE3 co-repressor complex by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia.
Fabrizio Simeoni, Tim Cp Somervaille

Mol Cell Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Mark S Williams, Naseer J Basma, Fabio M R Amaral, Daniel H Wiseman, Tim C P Somervaille

BMC Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia.
Fabrizio Simeoni, Isabel Romero-Camarero, Francesco Camera, Fabio M R Amaral, Oliver J Sinclair, Tim C P Somervaille

Cell Rep· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis